{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:16:07Z","timestamp":1788419767059,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bleomycin-induced pulmonary toxicity remains a significant complication of curative BEP chemotherapy for germ cell tumours, and no validated circulating biomarker enabling individual risk prediction or early detection of lung damage is currently available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This exploratory two-centre cohort study enrolled 60 patients with germ cell tumours receiving therapeutic three or four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy. A separate cohort of 18 patients with germ cell tumours receiving adjuvant single-cycle BEP was analysed independently. Plasma and urinary concentrations of surfactant protein D (SP-D) and soluble receptor for advanced glycation end-products (sRAGE) were evaluated before, during, and after BEP chemotherapy in relation to pulmonary toxicity, diffusing capacity of the lung for carbon monoxide (DLCO), pulmonary metastases, renal function, inflammatory indices, grade \u22653 neutropenia, febrile neutropenia, and other non-pulmonary toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Documented pulmonary toxicity developed in thirteen patients during or after BEP chemotherapy. Baseline plasma SP-D and sRAGE were not significantly associated with pulmonary toxicity (OR per doubling 0.60 [95% CI 0.27\u20131.37]; p=0.230 and OR 1.20 [95% CI 0.55\u20132.62]; p=0.640, respectively). The longitudinal increase of plasma SP-D during BEP chemotherapy was statistically significant (p=0.00018; n=30 with complete measurements), with a more pronounced increase associated with HRCT-confirmed pulmonary toxicity. Higher baseline urinary SP-D was significantly associated with lower post-treatment DLCO (Spearman coefficient rho=\u22120.609; p=0.001; FDR q=0.014). Plasma SP-D trajectories differed significantly according to the presence of pulmonary metastases (time \u00d7 metastases interaction: p=0.012; adjusted p=0.027). Maximum plasma sRAGE was statistically significantly associated with neutropenia and\/or febrile neutropenia during BEP chemotherapy (OR per doubling 12.13 [95% CI 2.59\u201356.93]; p=0.0016; FDR q=0.013), with this association remaining significant after correction for multiple testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with germ cell tumours receiving BEP chemotherapy, SP-D showed potential as a candidate monitoring biomarker of pulmonary injury during BEP chemotherapy. Greater SP-D increases were associated with HRCT-documented pulmonary toxicity in an exploratory analysis, whereas higher baseline urinary SP-D was significantly associated with impaired diffusing capacity of the lungs after treatment completion. Higher maximum plasma sRAGE was associated with neutropenia and\/or febrile neutropenia. These results support prospective validation of compartment-specific monitoring of SP-D and sRAGE during BEP chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1954888","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:48Z","timestamp":1788417828000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal plasma and urinary SP-D and sRAGE during BEP chemotherapy in germ cell tumours"],"prefix":"10.3389","volume":"17","author":[{"given":"Katarina","family":"Rejlekova","sequence":"first","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Vlkova","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute of Molecular Biomedicine, Comenius University","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Olah","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Pokrivcak","sequence":"additional","affiliation":[{"name":"Masaryk Memorial Cancer Institute","place":["Brno, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rateb","family":"Alzeer","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Escherova","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Chovanec","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lesko","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Obertova","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Orszaghova","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Palacka","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Sycova-Mila","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mego","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Celec","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute of Molecular Biomedicine, Comenius University","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8451","article-title":"Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin","volume":"34","author":"Lauritsen","year":"2016","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2005.01.007","article-title":"Bleomycin lung toxicity: who are the patients with increased risk","volume":"18","author":"Azambuja","year":"2005","journal-title":"Pulm Pharmacol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg020","article-title":"Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours","volume":"14","author":"O'Sullivan","year":"2003","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/480608","article-title":"Bleomycin-induced lung injury","volume":"2013","author":"Reinert","year":"2013","journal-title":"J Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.411","article-title":"Biomarkers of lung damage with possible predictiveness of ARDS within CS in super high-risk patients with germ cell tumors","volume":"38","author":"Rejlekova","year":"2020","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1861834","article-title":"Toxicity of BEP chemotherapy in germ cell tumors: Focus on immune-mediated bleomycin pulmonary toxicity in comparison with EP and VIP regimens","volume":"17","author":"Ol\u00e1h","year":"2026","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/01902148.2016.1215570","article-title":"Surfactant protein D is a useful biomarker for monitoring acute lung injury in rats","volume":"42","author":"Murata","year":"2016","journal-title":"Exp Lung Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.6.8520747","article-title":"Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids","volume":"152","author":"Honda","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.11.983","article-title":"Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury","volume":"58","author":"Eisner","year":"2003","journal-title":"Thorax"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5327-1","article-title":"Plasma sRAGE is independently associated with increased mortality in ARDS: a meta-analysis of individual patient data","volume":"44","author":"Jabaudon","year":"2018","journal-title":"Intensive Care Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201501-0020OC","article-title":"Soluble receptor for advanced glycation end-products predicts impaired alveolar fluid clearance in acute respiratory distress syndrome","volume":"192","author":"Jabaudon","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms141019891","article-title":"Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond","volume":"14","author":"Daffu","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0300-x","article-title":"Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK","volume":"119","author":"Watson","year":"2018","journal-title":"Br J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.460","article-title":"Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker","volume":"118","author":"Chovanec","year":"2018","journal-title":"Br J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13158","article-title":"The effect of pulmonary function testing on bleomycin dosing in germ cell tumours","volume":"46","author":"Roncolato","year":"2016","journal-title":"Intern Med J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1954888\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:49Z","timestamp":1788417829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1954888\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2026.1954888"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1954888","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1954888"}}